Ascendis Pharma A/S (ASND)

Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years.

On February 19, Tom Lee of Fundstrat and BitMine joined 'Closing Bell' on CNBC to talk about the state of the markets.

Operator: At this time, participants are in listen-only mode. Thank you for standing by, and welcome to the Ascendis Pharma A/S Fourth Quarter 2025 Earnings Conference Call.

Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best high growth European stocks to buy.

In other news, on January 20, TheFly reported that Wells Fargo analyst Derek Archila upgraded the price target on Ascendis Pharma from $322 to $330, keeping an Overweight rating on the stock.

Following growing uncertainty in global markets amid heightened geopolitical tensions, the U.S. market rebounded this week.

European equities began the last week of January in a sour mood, with investors concerned on January 26 about rising geopolitical tensions in anticipation of a Federal Reserve policy meeting and a flood...

We came across a bullish thesis on Ascendis Pharma A/S on Tip Ranks’ YouTube Channel. In this article, we will summarize the bulls’ thesis on ASND.

Operator: Good day, and welcome to the Third Quarter 2025 Pharma Earnings Conference Call. At this time, participants are in a listen-only mode.